Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Vomiting 8Nausea 5Neoplasms 3Lymphoma 3Breast Neoplasms 3Leukemia 2Uterine Neoplasms 1Thyroid Neoplasms 1Sezary Syndrome 1Pruritus 1Post-Dural Puncture Headache 1Ovarian Neoplasms 1Hematologic Neoplasms 1

Interventions

lenvatinib 3cabozantinib 2Thyrotropin Alfa 2vandetanib 1trametinib 1sintilimab 1selpercatinib 1pralsetinib 1pembrolizumab 1pazopanib 1palbociclib 1olaparib 1larotrectinib 1dabrafenib 1anlotinib 1acetaminophen, codeine drug combination 1Tramadol 1Thyroxine 1Technetium Tc 99m Sestamibi 1Sunitinib 1Sodium Chloride 1Ondansetron 1Negative-Pressure Wound Therapy 1Indocyanine Green 1Fentanyl 1Conversion to Open Surgery 1Capsules 1Aprepitant 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Thyroid Neoplasms × Aprepitant × Clear all
NCT06697782 2025-01-22

Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer

The First Affiliated Hospital of Zhengzhou University

Phase 4 Completed
600 enrolled
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡